United StatesThe article discusses recent developments in pharmaceutical research, including the pause of cell therapy trials by Novartis and Bristol Myers Squibb due to observed inflammatory side effects. Specifically, three patients in Novartis' trial of the CAR-T therapy rap-cel died from severe immune reactions, prompting a halt in trials. Bristol Myers Squibb has also paused enrollment in trials for its CAR-T treatment zola-cel. The article notes that both therapies use newer technology aimed at accelerating production. Additionally, it mentions President Trump's announcement of new pricing deals with nine drugmakers, which include commitments to lower drug prices and improve access for U.S. patients, though specific deal details remain undisclosed.
Bias read (Center): The article presents information on both pharmaceutical industry developments and government policy regarding drug pricing. While the pharmaceutical updates involve significant health implications, the framing remains neutral, presenting facts without overt ideological slant. The discussion of drug価
